MONUROL
Pronunciation: fos-foe-MYE-sin

What it isInhibitor of an early step in cell wall synthesis; uncomplicated cystitis.
Why this oneSingle oral dose treats cystitis, and it retains activity against many multidrug-resistant organisms.
What limits itConcentrates only in urine, so it is useless for pyelonephritis or systemic infection.
Animated chart of estimated U.S. prescriptions per year, Antibacterials (systemic) (1938–2026). Fosfomycin enters in 1997 (estimated).
Principal riskUrine only, so useless in pyelonephritis
Legacy pregnancy categoryUnknown / historical label unavailable
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.
Read the full label on DailyMed ↗
NO BOXED WARNINGS
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Uncomplicated UTI (acute cystitis) | Women ≥18 y | One 3 g sachet single dose | One 3 g sachet single dose | One 3 g sachet single dose |
Renal Undefined
Hepatic Undefined
Single-dose therapy; do not use multiple doses to treat a single episode of acute cystitis.
Available strengths
Pregnancy Crosses the placental barrier; not teratogenic in animal studies.
Lactation Undefined
| Strength | #/mo | generic $/unit | CostPlus | |
|---|---|---|---|---|
| 3 g/packet | sol | per unit | $26.22/ea | offered |
Generic entry2020
Open Fosfomycin in the interactive console ↗